Simurosertib NEW

Price	$68	$97	$189
Package	1mg	2mg	5mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19

Product Details

Product Name: Simurosertib	CAS No.: 1330782-76-7
Purity: 99.93%	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	Simurosertib
Description	Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).
In vitro	Simurosertib effectively inhibits CDC7 kinase activity (IC50 <0.3 nM) with time-dependent ATP-competitive kinetics to its ATP-binding pocket. Treatment with Simurosertib inhibits the cellular MCM2 phosphorylation at Ser40 in a dose-dependent manner, resulting in a delayed S phase progression, DNA-damage checkpoint activation, and caspase-3/7 activation. The selectivity studies using the 308 kinases reveals >120-fold selectivity of Simurosertib for CDC7 kinase inhibition compared to other kinase inhibitions [1].
In vivo	Simurosertib (p.o.) inhibits pMCM2 of the xenografted COLO205 in a dose- and time-dependent manner in the COLO205-xenograft mouse model. Simurosertib shows a significant antitumor activity in multiple xenograft models [1].
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 45 mg/mL (131.8 mM), Sonication is recommended.
Keywords	Inhibitor \| anti-cancer \| Cyclin dependent kinase \| ATP-competitive \| TAK931 \| CDK \| cycle \| Simurosertib \| cell \| orally \| inhibit \| TAK 931 \| division
Inhibitors Related	Ribociclib \| Ro-3306 \| GSK 3 Inhibitor IX \| Rafoxanide \| Palbociclib monohydrochloride \| CASIN \| Palbociclib \| GW 441756 \| Sodium Oxamate \| Abemaciclib \| Dinaciclib \| Abemaciclib methanesulfonate
Related Compound Libraries	Bioactive Compound Library \| Kinase Inhibitor Library \| Anti-Cancer Clinical Compound Library \| Drug Repurposing Compound Library \| Inhibitor Library \| Anti-Aging Compound Library \| Bioactive Compounds Library Max \| Anti-Cancer Compound Library \| Anti-Cancer Drug Library \| Anti-Cancer Active Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.